Get started
Author

Shodeinde A. Coker

Observed names: Shodeinde A Coker, Shodeinde Coker
ORCID: 0000-0003-2263-5923
Observed ORCID: 0000-0003-2263-5923
OpenAlex ID: A5042005167
Kynurenine‐Induced Aryl Hydrocarbon Receptor Signaling in Mice Causes Body Mass Gain, Liver Steatosis, and Hyperglycemia
2021 · Itzel Y. Rojas, Benjamin J. Moyer, et al. · Obesity · 52
PDF
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
2022 · John Hilton, Mihaela Cristea, et al. · Cancers · 44
PDF
A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers
2017 · Shodeinde A. Coker, Zbigniew M. Szczepiorkowski, et al. · Transfusion Medicine Reviews · 43
Levamisole‐induced occlusive necrotising vasculitis in cocaine abusers: an unusual cause of skin necrosis and neutropenia
2012 · Cassius D Belfonte, Victoria K Shanmugam, et al. · International Wound Journal · 21
PDF
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
2020 · Sivraj Muralikrishnan, Lara K. Ronan, et al. · Case Reports in Oncology · 12
PDF
Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy
2017 · Shodeinde A Coker, David A Pastel, et al. · SAGE Open Medical Case Reports · 8
PDF
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
2023 · David Lavie, Vincent Ribrag, et al. · Blood · 7
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation
2023 · Michael L. Cheng, Yeying Huang, et al. · JCO Precision Oncology · 7
PDF
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer
2017 · Kevin M. Koch, E. Claire Dees, et al. · Cancer Chemotherapy and Pharmacology · 5
BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
2022 · Rosa Ayala, Nieves Lopez, et al. · Blood · 4
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours
2013 · Shodeinde A. Coker, Uday B. Dandamudi, et al. · Journal of Chemotherapy · 4
NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies
2025 · Cindy Zhang, Ke Xu, et al. · Frontiers in Medicine · 3
PDF
Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein
2022 · Zheng Yang, James Loy, et al. · Frontiers in Pharmacology · 3
PDF
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
2019 · Shodeinde A. Coker, Herbert I. Hurwitz, et al. · Cancer Chemotherapy and Pharmacology · 3
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
2023 · Rosa Ayala, Nieves Lopez, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158
2020 · Xi (Cindy) Chen, Lora Hamuro, et al. · Cancer Research · 2
The In Vivo Recovery/Survivaland Pharmacokinetic Properties of Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes
2016 · Shodeinde Coker, Zbigniew M Szczepiorkowski, et al. · Blood · 2
Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)
2023 · Si Tuen Lee-Hoeflich, Christopher Brueckner, et al. · Blood
POSTER: MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
2023 · Rosa Ayala, Nieves Lopez, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
S213: Bms-986158, a Potent Bet Inhibitor, as Monotherapy and in Combination With Ruxolitinib or Fedratinib in Intermediate- or High-risk Myelofibrosis (mf): Results From a Phase 1/2 Study
2023 · Rosa Ayala, Nieves Lopez, et al. · HemaSphere
Abstract 1742: Inhibition of BET signaling leads to reversible GATA1-associated repression of hematopoietic progenitors: translation from preclinical assessment to clinical development
2020 · Cindy Zhang, Ke Xu, et al. · Cancer Research
Works count: 21
Citation count: 222
H-index: 7
I10-index: 5
Year
Topic
Type